Allianz Asset Management
GLUE icon

Allianz Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Allianz Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-121,750
Closed -$1.18M – 1984
2022
Q2 		$1.18M Buy
121,750
+29,253
+32% +$294K ﹤0.01% 1618
2022
Q1 		$1.3M Buy
+92,497
New +$1.28M ﹤0.01% 1747

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allianz Asset Management's GLUE Position: Q3 2022 in Review

Allianz Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2022, closing a stake of 121,750 shares — an estimated $1.18M sold.

Allianz Asset Management first reported a position in GLUE in Q1 2022 and held it in 2 quarters. The position peaked at $1.3M in Q1 2022. 70 funds tracked by Wall St. Rank hold GLUE as of Q3 2022.

  • Allianz Asset Management reported no remaining Monte Rosa Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 121,750 Monte Rosa Therapeutics shares in Q3 2022, an estimated $1.18M.
  • Allianz Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2022 and held it in 2 quarters.
  • Allianz Asset Management's Monte Rosa Therapeutics position peaked at $1.3M in Q1 2022.
  • 70 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.